Sign In
Buy NBIX
$167.35
+2.24 (+1.36%)
At Close: Jun 04, 2026
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
08:00am, Wednesday, 30'th Apr 2025
SAN DIEGO , April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerabil
Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern SAN DIEGO ,
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
06:05pm, Tuesday, 22'nd Apr 2025
Company's valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in 2025, targeting patients unresponsive to antipsychotics. The company also anticipates phas
Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity
05:51pm, Wednesday, 16'th Apr 2025
Neurocrine Biosciences, Inc. has shown significant growth since its 1996 IPO, with a current stock price around $100, reflecting an 850% increase. Ingrezza is the flagship, >$2bn p.a. selling product.
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
08:00am, Friday, 04'th Apr 2025
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO , April 4, 2025 /PRNewswire/ -- Neurocrin
All Patients Treated with INGREZZA® (valbenazine) Capsules Reached a Therapeutic Dose from Day One, While Only Approximately Half of Patients Treated with Deutetrabenazine Were Able to Reach a Therap
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
07:00pm, Wednesday, 26'th Mar 2025
Explore the exciting world of Neurocrine Biosciences (NBIX -1.47%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market tren
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
08:30am, Thursday, 20'th Mar 2025
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN D
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
03:01pm, Monday, 17'th Mar 2025
If you work in the biotech industry, you might know the name Alex Denner.
Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
04:01pm, Tuesday, 11'th Mar 2025
SAN DIEGO , March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025.
SAN DIEGO , March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics
SAN DIEGO , Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustai
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
04:01pm, Tuesday, 25'th Feb 2025
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief Financial
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
08:00am, Friday, 21'st Feb 2025
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocri
